Table 1.
General characteristics of patients
| Patient No | Age | Gender | Estimated BW/BH | Days from admission to intubation | Days from admission to diagnosis | PCR( ±) | Chest CT reading | Comorbidities | Respiratory support before tracheal intubation | Device used for intubation | Drugs used for induction | Drugs used for resuscitation | Any difficulties for tracheal intubation | Prognosis on 7-day after intubation | Current status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 72 | M | 60 kg/168 cm | 3 | 2 | + | Ground-glass opacities | None | NPPV | TDC-C® | Propofol 70 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | Discharged |
| 2 | 56 | M | 67 kg/170 cm | 4 | 3 | + | Ground-glass opacities | HBD,Prostate cancer | NPPV | TDC-C® | Propofol 80 mg, Rocuronium 90 mg | Ephedrine 6 mg | None | Dead | Dead |
| 3 | 66 | M | 70 kg/175 cm | 11 | 3 | + | Ground-glass opacities | Gout | NPPV | TDC-C ® | Propofol 90 mg, Rocuronium 90 mg | Ephedrine 6 mg | None | Dead | Dead |
| 4 | 57 | F | 65 kg/158 cm | 9 | 4 | + | Ground-glass opacities | DM,Liver space occupying lesion | NPPV | TDC-C ® | Propofol 80 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | On ventilator |
| 5 | 67 | F | 60 kg/155 cm | 6 | 4 | + | Ground-glass opacities | ARDS | NPPV | TDC-C ® | Propofol 70 mg, Rocuronium 80 mg | Ephedrine 8 mg | None | Dead | Dead |
| 6 | 79 | F | 60 kg/155 cm | 9 | 3 | + | Ground-glass opacities | Carotid stenosis | NPPV | TDC-C ® | Propofol 70 mg, Rocuronium 90 mg | Ephedrine 6 mg | None | Alive | Dead |
| 7 | 69 | F | 65 kg/158 cm | 7 | 2 | + | Ground-glass opacities | CHD,HBD, OMI | NPPV | TDC-C ® | Propofol 80 mg, Rocuronium 90 mg | Ephedrine 8 mg | None | Dead | Dead |
| 8 | 81 | F | 60 kg/155 cm | 7 | 3 | + | Ground-glass opacities | HBD,DM,CHD, CS | NPPV | TDC-C ® | Propofol 60 mg, Rocuronium 60 mg | Ephedrine 6 mg | None | Alive | On ventilator |
| 9 | 81 | F | 55 kg/156 cm | 7 | 4 | + | Ground-glass opacities | HBD,CHD | NPPV | TDC-C ® | Propofol 70 mg, Rocuronium 70 mg | Ephedrine 6 mg | None | Alive | Dead |
| 10 | 71 | F | 58 kg/157 cm | 10 | 3 | + | Ground-glass opacities | HBD,CHD,DM,CI | NPPV | TDC-C ® | Propofol 60 mg, Rocuronium 70 mg | Ephedrine 8 mg | None | Dead | Dead |
| 11 | 64 | M | 70 kg/170 cm | 8 | 4 | + | Ground-glass opacities | HBD,Sinus arrest | NPPV | TDC-C ® | Propofol 90 mg, Rocuronium 90 mg | Ephedrine 6 mg | None | Alive | Dead |
| 12 | 80 | M | 68 kg/168 cm | 7 | 3 | + | Ground-glass opacities | None | NPPV | TDC-C ® | Propofol 70 mg, Rocuronium 70 mg | Ephedrine 6 mg | None | Dead | Dead |
| 13 | 70 | M | 70 kg/168 cm | 8 | 3 | + | Ground-glass opacities | None | HFNC | TDC-C ® | Propofol 70 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | ECMO |
| 14 | 64 | M | 75 kg/160 cm | 12 | 5 | + | Ground-glass opacities | CFR | HFNC | TDC-C ® | Propofol 80 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Dead | Dead |
| 15 | 73 | F | 60 kg/160 cm | 14 | 5 | + | Ground-glass opacities | HBD,Hypothyroidism | NPPV | TDC-C ® | Propofol 60 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | ECMO |
| 16 | 69 | F | 60 kg/158 cm | 13 | 6 | + | Ground-glass opacities | None | HFNC | TDC-C ® | Propofol 60 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | On ventilator |
| 17 | 83 | M | 70 kg/172 cm | 12 | 5 | + | Ground-glass opacities | HBD | NPPV | TDC-C ® | Propofol 60 mg, Rocuronium 70 mg | Ephedrine 6 mg | None | Alive | Dead |
| 18 | 70 | M | 72 kg/168 cm | 12 | 4 | + | Ground-glass opacities | HBD | NPPV | TDC-C ® | Propofol 70 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | On ventilator |
| 19 | 71 | M | 65 kg/175 cm | 20 | 6 | + | Ground-glass opacities | HBD,Valvular heart disease, Liver dysfunction | NPPV | TDC-C ® | Propofol 80 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | Dead |
| 20 | 81 | M | 67 kg/168 cm | 23 | 4 | + | Ground-glass opacities | None | NPPV | TDC-C ® | Propofol 60 mg, Rocuronium 80 mg | Ephedrine 6 mg | None | Alive | On ventilator |
HBP high blood pressure or hypertension, DM diabetes mellitus, CI cerebral infarction, CS cerebral stroke, CHD coronary atherosclerotic heart disease, OMI old myocardial infarction, CFR chronic renal insufficiency, ARDS acute respiratory distress syndrome, NPPV noninvasive positive pressure ventilation, HFNC high-flow nasal cannula oxygen, ECMO extracorporeal membrane oxygenation, TDC-C ® TDC-C video laryngoscope ® (UE World)